Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Dana-Farber Cancer Institute Genentech |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00722865 |
The purpose of this research study is to determine the effectiveness and safety of Avastin when combined with standard chemotherapy for Hodgkin lymphoma. Avastin works differently than standard chemotherapy drugs. It is a type of protein called an antibody which binds to a substance called VEGF(Vascular Endothelial Growth Factor).
VEGF stimulates the growth of the blood vessels that feed tumors and encourages tumor cell growth. VEGF is produced in excess by Hodgkin lymphoma cells, and is associated with a poorer outcome in patients with Hodgkin lymphoma. When the activity of VEGF is interrupted in multiple other cancer types, the blood vessels around the tumor cells die resulting in less nutrient delivery and death to the tumor. Blocking of VEGF has also been shown to improve delivery of chemotherapy to cancer cells, making standard chemotherapy work better. This trial uses Avastin in combination with standard chemotherapy with the goal of improving the cure rate over chemotherapy alone.
Condition | Intervention | Phase |
---|---|---|
Hodgkin Lymphoma |
Drug: Avastin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Avastin (Bevacizumab) in Combination With ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma |
Estimated Enrollment: | 36 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | August 2012 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Participants will be given Avastin as well as ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) intravenously on days 1 and 15 of a 28 day cycle. Participants will receive up to a total of 6 cycles of therapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kathleen Shea | 617-724-9190 | kshea@partners.org |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Jeremy S Abramson, M.D. 617-724-4000 jabramson@partners.org | |
Principal Investigator: Jeremy Abramson, MD | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Ann S LaCasce, M.D. 617-632-3352 alacasce@partners.org | |
Principal Investigator: Ann LaCasce, MD |
Principal Investigator: | Jeremy Abramson, MD | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Jeremy Abramson, MD ) |
Study ID Numbers: | 07-388 |
Study First Received: | July 24, 2008 |
Last Updated: | July 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00722865 History of Changes |
Health Authority: | United States: Institutional Review Board |
Avastin bevacizumab ABVD |
angiogenesis antiangiogenic Hodgkin |
Immunoproliferative Disorders Dacarbazine Hodgkin Lymphoma, Adult Hodgkin's Disease Vinblastine Bevacizumab Bleomycin |
Angiogenesis Inhibitors Doxorubicin Lymphatic Diseases Lymphoproliferative Disorders Lymphoma Hodgkin Disease |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents Growth Substances Physiological Effects of Drugs Bevacizumab Angiogenesis Inhibitors Pharmacologic Actions |
Lymphatic Diseases Neoplasms Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Lymphoproliferative Disorders Hodgkin Disease Lymphoma |